Strain-Independent Therapeutic Antibodies for Influenza

流感病毒毒株无关的治疗性抗体

基本信息

批准号：
9093684
负责人：
Lawrence Michael Kauvar
金额：
$ 98.73万
依托单位：
TRELLIS BIOSCIENCE, INC.
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-07-01 至 2018-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9093684
关键词：
Acute Advanced Development Affect Affinity Animals Antibodies Antigens Antiviral Agents Arts Binding Biodistribution Biological Biological Sciences Birds Cell Line Cells Clinical Clinical Trials Communicable Diseases Cytomegalovirus Disease Dose Epitopes Event Family suidae Ferrets Formulation Genetic Recombination Half-Life Health Hemagglutinin Human Immunity Immunohistochemistry In Vitro Infection Influenza Influenza A Virus, H1N1 Subtype Influenza A virus Influenza B Virus Lung Marketing Mediating Modeling Monoclonal Antibodies Monoclonal Antibody Therapy Mus Pathology Phase Population Pre-Clinical Model Production Prophylactic treatment Proteins Publishing Respiratory syncytial virus Route Sentinel Serum Site Specificity Staging T-Lymphocyte Technology Testing Therapeutic Therapeutic Agents Therapeutic antibodies Toxic effect Toxicity Tests Toxicology Transfection Virus Work base biosafety level 3 facility cell bank cost design human disease human monoclonal antibodies human tissue immunogenic improved in vitro activity in vivo influenzavirus innovation method development monoclonal antibody production mouse model novel therapeutics pandemic disease pathogen programs screening seasonal influenza

项目摘要

DESCRIPTION (provided by applicant): Trellis Bioscience's CellSpot" technology for identification of rare human antibodies with high specificity and affinity against multiple antigen has enabled discovery of highly efficacious strain- independent antibodies to Respiratory Syncytial Virus and to Cytomegalovirus. We have now applied CellSpot to isolate two native human antibodies with broad reactivity to Group 1 and Group 2 influenza A strains respectively. Both of these antibodies have now been shown to have in vivo efficacy. In addition, we have isolated a human antibody with in vitro activity against Influenza B. We propose to advance these therapeutic candidates to IND stage, including additional neutralization studies in vitro and in vivo, manufacturing, toxicity, and PK studies. The resulting clinical candidates are expected to provide potent post-infection antiviral activity against all currently circulating strains, and effective prophylaxis against any emerging pandemic strain.

描述（由申请人提供）：格子生物科学的细胞点“用于鉴定具有高特异性和对多种抗原亲和力的稀有人类抗体的技术，使得发现了对呼吸道合成病毒的高效菌株独立抗体的高度抗体抗体，并针对细胞cypot cellspot进行了分离的人类抗体，并将其应用于cypot。这两种抗体现已显示出具有体内功效。体内，制造，毒性和PK研究。预计由此产生的临床候选者针对所有当前循环菌株提供有效的感染后抗病毒活性，并有效预防任何新出现的大流行菌株。